Objective:
To present and launch the Voyager direct selective laser trabeculoplasty (DSLT) at the 2025 American Glaucoma Society meeting.
Key Findings:
- Voyager DSLT is an automated, contact-free laser trabeculoplasty.
- Demonstrated noninferiority to traditional SLT at 6 months.
- Excellent efficacy and safety observed up to 12 months.
Interpretation:
The Voyager DSLT addresses the growing need for efficient laser trabeculoplasty as a primary treatment for open-angle glaucoma.
Limitations:
- Long-term data beyond 12 months is not yet available.
- Further studies may be needed to confirm findings across diverse patient populations.
Conclusion:
The Voyager DSLT is a significant advancement in glaucoma treatment, expected to enhance the role of laser trabeculoplasty as a first-line therapy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.